Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / June / Testicular Cancer Blood Test Shows Promise
Oncology Liquid biopsy Microbiology and Immunology Research and Innovations

Testicular Cancer Blood Test Hopes

A newly developed serum immunosignature assay could improve detection of germ cell tumors, including cases missed by conventional tumor markers

06/12/2026 News 2 min read
  • Full Article
  • Summary
  • Listen
  • Report
  • Poll
  • Top Institutions
  • Topic Commentary

Share

Clinical Report: Testicular Cancer Blood Test Hopes

Overview

A novel blood test based on immune responses accurately identifies testicular cancer, detecting cases missed by standard markers. Developed by Mayo Clinic, the GCT-iSIGN assay shows potential for improved diagnosis.

Background

Testicular cancer is a prevalent malignancy among young men, and accurate diagnosis is crucial for effective treatment. Current serum markers often fail to detect the disease, especially in seminoma cases.

Data Highlights

ParameterResult
Cases identified by GCT-iSIGN23 of 24
Conventional markers missedMost cases
Diagnostic performance across stagesConsistent

Key Findings

  • The GCT-iSIGN assay uses phage immunoprecipitation sequencing to identify cancer-specific immunosignatures.
  • It was validated using 427 serum samples, including those from patients with testicular germ cell tumors.
  • The test identified nearly all cases lacking elevations in conventional biomarkers.
  • It maintained diagnostic performance regardless of tumor volume.
  • A second immunosignature panel could distinguish between seminoma and nonseminoma tumors.

Clinical Implications

The GCT-iSIGN assay may provide a more sensitive diagnostic tool for testicular cancer.

Conclusion

The findings indicate that immune-signature assays could enhance the accuracy of testicular cancer diagnosis.

Related Resources & Content

  1. Mayo Clinic, Nature Communications, 2024 -- Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor–specific immunosignature
  2. The ASCO Post — Can Blood Test Predict Survival in Metastatic Prostate Cancer?
  3. The ASCO Post — Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease
  4. fox chase cancer center — Combined Tests Could Reduce Unnecessary Bladder Removal
  5. the asco post — Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
  6. EAU Guidelines on Testicular Cancer - INTRODUCTION
  7. Can Blood Test Predict Survival in Metastatic Prostate Cancer?
  8. Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease
  9. Combined Tests Could Reduce Unnecessary Bladder Removal
  10. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Testicular-Cancer-2024.pdf
  11. Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor–specific immunosignature | Nature Communications

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

A Light in the Darkness
Liquid biopsy
A Light in the Darkness

March 4, 2022

2 min read

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

Biomarkers: The Bigger Picture
Liquid biopsy
Biomarkers: The Bigger Picture

April 27, 2022

1 min read

To unlock patient care, pathologists must focus on molecular pathology and ensure efficiency and effectiveness to improve testing. With this testing, patients can benefit from the best treatment to combat their disease.

Benchmarking… Liquid Biopsy
Liquid biopsy
Benchmarking… Liquid Biopsy

May 13, 2022

1 min read

A look at the last five years of publishing on liquid biopsy

Does Your Blood Know You Have Cancer?
Liquid biopsy
Does Your Blood Know You Have Cancer?

July 25, 2022

2 min read

Detection and monitoring are crucial for melanoma outcomes – could a blood test revolutionize both?

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.